Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib for multiple myeloma with renal impairment
ACTRN12614000301662Phase 2Completed
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Apr 2015
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of carfilzomib in multiple myeloma (MM), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoints: Early change in serum free light chains after carfilzomib and Relationship between early serum free light chain change and renal function after 4 cycles. Started Apr 2015; status: completed.
02
Drugs
carfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ACTRN12614000301662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614000301662.